Amit Mahipal

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

Laura Q.M. Chow, Robert I. Haddad, Shilpa Gupta et al. · Journal of Clinical Oncology · 2016 · 859 citations · Full text

Medicine, Oncology, Pharmacology +17

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

Michael S. Lee, Baek‐Yeol Ryoo, Chih‐Hung Hsu et al. · The Lancet Oncology · 2020 · 567 citations

Medicine, Oncology, Pharmacology +14

Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma

Lipika Goyal, Funda Meric‐Bernstam, Antoine Hollebecque et al. · New England Journal of Medicine · 2023 · 541 citations · Full text

Medicine, Oncology, Pharmacology +16

A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer

Richard D. Kim, Vincent Chung, Olatunji B. Alese et al. · JAMA Oncology · 2020 · 449 citations · Full text

Medicine, Oncology, Pharmacology +16

Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer

Mark J. Truty, Michael L. Kendrick, David M. Nagorney et al. · Annals of Surgery · 2019 · 437 citations · Full text

Medicine, Perioperative Medicine, Surgery +13